# Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)

> **NCT03909165** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 145 (actual)

## Conditions studied

- Neuromuscular Blockade

## Interventions

- **DRUG:** Sugammadex 2 mg/kg
- **DRUG:** Sugammadex 4 mg/kg
- **DRUG:** Neostigmine + Glycopyrrolate
- **DRUG:** Neostigmine + Atropine

## Key facts

- **NCT ID:** NCT03909165
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-23
- **Primary completion:** 2023-09-21
- **Final completion:** 2023-09-21
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2025-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03909165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03909165, "Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03909165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*